Netarsudil and latanoprost combo useful fixed dose option for open-angle glaucoma and IOP: Study

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-04-16T20:45:40+05:30 | Updated On 17 April 2024 11:55 AM IST

A recent study published in the Graefe's Archive for Clinical and Experimental Ophthalmology compared the effectiveness and safety of two fixed-dose combination (FDC) ophthalmic solutions for treating open-angle glaucoma (OAG) and ocular hypertension (OHT). This study evaluated the efficacy of the FDC of netarsudil 0.02%/latanoprost 0.005% (NET/LAT; Roclanda®) against bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort®).

Over a 6-month period, the MERCURY-3 study included patients over 18 years with OAG or OHT that was insufficiently controlled by topical medication. The efficacy and safety of NET/LAT and BIM/TIM were assessed at various intervals throughout the study.

The results indicated that NET/LAT was non-inferior to BIM/TIM in reducing intraocular pressure (IOP), with no statistically significant difference between the two treatments. Both treatments demonstrated a mean diurnal IOP ranging from 15.2 to 15.6 mmHg, where NET/LAT showed comparable efficacy to BIM/TIM. Also, no treatment-related adverse events were observed, with most adverse events being mild to moderate in severity.

The most common treatment-related adverse events were conjunctival hyperemia and cornea verticillata, where NET/LAT showed slightly higher rates of conjunctival hyperemia when compared to BIM/TIM. Further, these adverse events were consistent with previous findings and did not pose significant safety concerns.

This research emphasized the significance of the findings by stating that once-daily NET/LAT provides a compelling alternative to the fixed-dose combination treatment option for patients with OAG and OHT. This study offers valuable insights into the efficacy and safety profile of NET/LAT that expands the treatment options for individuals with these sight-threatening conditions.

Reference:

Stalmans, I., Lim, K. S., Oddone, F., Fichtl, M., Belda, J. I., Hommer, A., Laganovska, G., Schweitzer, C., Voykov, B., Zarnowski, T., & Holló, G. (2023). MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. In Graefe’s Archive for Clinical and Experimental Ophthalmology (Vol. 262, Issue 1, pp. 179–190). Springer Science and Business Media LLC. https://doi.org/10.1007/s00417-023-06192-0

Graefe’s Archive for Clinical and Experimental Ophthalmologyopen-angle glaucomaocular hypertension

Source : Graefe’s Archive for Clinical and Experimental Ophthalmology

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751